MPS VI Clinical Surveillance Program CSP)
Research payments
$359,989
Through program year 2022, $359,989 in research payments was reported against MPS VI Clinical Surveillance Program CSP), across 42 payments, paid by BioMarin Pharmaceutical Inc..
- Paid by
- BioMarin Pharmaceutical Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $6,325 | 1 |
| 2021 | Research | $317,114 | 17 |
| 2020 | Research | $36,550 | 24 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Vikas Bhambhani Minneapolis, MN Named on 5 payments
- Virginia Kimonis Orange, CA Named on 4 payments
- Bryan Hainline Indianapolis, IN Named on 4 payments
- Linda Randolph Los Angeles, CA Named on 3 payments
- Laura Davis Keppen Sioux Falls, SD Named on 3 payments
- Barbara Burton Chicago, IL Named on 2 payments
- Laurie Demmer Charlotte, NC Named on 2 payments
- Heather Lau New York, NY Named on 2 payments
- Nicola Longo Salt Lake City, UT Named on 2 payments
- Paul Harmatz Oakland, CA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.